LGC agreed to acquire Biosearch Technologies, which designs, develops, and manufactures custom oligonucleotides and associated reagents for the medical diagnostics, research, and applied markets. Biosearch’s products, which are used in the amplification, detection, and quantification of DNA molecules, are targeted at the molecular diagnostics market, as well as to the applied and research sectors of the genomics market. The company develops molecular assays to improve testing and diagnosis of human disease and improve yields and disease resistance in animal and plant breeding programs. Biosearch works with the world’s top 12 molecular diagnostics companies and operates from state of the art facilities in the U.S. and Europe, with headquarters in Petaluma, California.
“We are delighted to join our teams, science and expertise together,” Tim Robinson, CEO of LGC said in a statement. “Through its facilities in Petaluma and Novato (U.S.), Aarhus (Denmark), and Steinach (Germany), Biosearch is a significant global supplier of custom oligonucleotides as well as reagents for their synthesis. Both LGC and Biosearch have a complementary range of products thus allowing us to provide customers with a one-stop shop for a wide range of genomics applications. We will continue to supply all Biosearch products as well as investing in its development and facilities. With this acquisition, we are strengthening our position within the applied genomics market, especially the agricultural biotechnology sector, and broadening our offering to the molecular diagnostics market. Integrating Biosearch’s products, its expertise within the qPCR and molecular diagnostics markets, and its world class manufacturing capabilities with LGC’s operations will provide many opportunities to expand our genomics business globally.”